Ei, A Pharmaceutical SolutionWorks, has signed agreements with European-based professors and technologists for the exclusive worldwide license of a novel class of sphingolipids. Sphingolipids are thought to play a critical role in strengthening the barrier function of the skin, promoting moisture retention and increasing elasticity of the skin. Ei has been granted options on several related technologies in various stages of development.
 
In preliminary clinical studies, the technology demonstrated significantly better barrier function with substantial improvement in moisture retention when compared to commercially available sphingolipid compounds. 
 
“As A Pharmaceutical SolutionWorks, this investment in intellectual property demonstrates Ei’s mission to offer our customers value beyond typical development and manufacturing capability,” said Michael Kane, chief executive officer of Ei. “Our customers have asked for unique, efficacious and highly protected ways to innovate for their customers and enhance the value of their brands.”